Sökning: WFRF:(Steg Philippe Gabriel)
> (2015-2019) >
Lipoprotein-Associa...
Lipoprotein-Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
-
- Wallentin, Lars (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Held, Claes (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Armstrong, Paul W. (författare)
- Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada.
-
visa fler...
-
- Cannon, Christopher P. (författare)
- Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.;Harvard Clin Res Inst, Boston, MA USA.
-
- Davies, Richard Y. (författare)
- GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, King Of Prussia, PA USA.
-
- Granger, Christopher B. (författare)
- Duke Univ, Med Ctr, Durham, NC USA.
-
- Hagström, Emil (författare)
- Uppsala universitet,Kardiologi
-
- Harrington, Robert A. (författare)
- Stanford Univ, Dept Med, Stanford, CA 94305 USA.
-
- Hochman, Judith S. (författare)
- NYU, Langone Med Ctr, Dept Med, New York, NY USA.
-
- Koenig, Wolfgang (författare)
- Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, Ulm, Germany.;Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany.;DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany.
-
- Krug-Gourley, Sue (författare)
- GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, King Of Prussia, PA USA.
-
- Mohler, Emile R., III (författare)
- Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
-
- Siegbahn, Agneta (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
- Tarka, Elizabeth (författare)
- GlaxoSmithKline, Former Employee Metab Pathways & Cardiovasc Thera, King Of Prussia, PA USA.
-
- Steg, Philippe Gabriel (författare)
- FACT, Paris, France.;Univ Paris Diderot, Sorbonne Paris Cite, DHU FIRE, Paris, France.;Hop Bichat Claude Bernard, INSERUM, U 1148, Paris, France.;Imperial Coll, Royal Brompton Hosp, ICMS, NHLI, London, England.
-
- Stewart, Ralph A. H. (författare)
- Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.;Univ Auckland, Auckland 1, New Zealand.
-
- Weiss, Robert (författare)
- Maine Res Associates, Auburn, ME USA.
-
- östlund, Ollie (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
- White, Harvey D. (författare)
- Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.;Univ Auckland, Auckland 1, New Zealand.
-
visa färre...
-
(creator_code:org_t)
- 2016
- 2016
- Engelska.
-
Ingår i: Journal of the American Heart Association. - 2047-9980. ; 5:6
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background - We evaluated lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp-PLA(2) inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial.Methods and Results - Plasma Lp-PLA(2) activity was determined at baseline (n=14 500); at 1 month (n=13 709); serially (n=100) at 3, 6, and 18 months; and at the end of treatment. Adjusted Cox regression models evaluated associations between Lp-PLA(2) activity levels and outcomes. At baseline, the median Lp-PLA(2) level was 172.4 mu mol/min per liter (interquartile range 143.1-204.2 mu mol/min per liter). Comparing the highest and lowest Lp-PLA(2) quartile groups, the hazard ratios were 1.50 (95% CI 1.23-1.82) for the primary composite end point (cardiovascular death, myocardial infarction, or stroke), 1.95 (95% CI 1.29-2.93) for hospitalization for heart failure, 1.42 (1.07-1.89) for cardiovascular death, and 1.37 (1.03-1.81) for myocardial infarction after adjustment for baseline characteristics, standard laboratory variables, and other prognostic biomarkers. Treatment with darapladib led to a approximate to 65% persistent reduction in median Lp-PLA(2) activity. There were no associations between on-treatment Lp-PLA(2) activity or changes of Lp-PLA(2) activity and outcomes, and there were no significant interactions between baseline and on-treatment Lp-PLA(2) activity or changes in Lp-PLA(2) activity levels and the effects of darapladib on outcomes.Conclusions - Although high Lp-PLA(2) activity was associated with increased risk of cardiovascular events, pharmacological lowering of Lp-PLA(2) activity by approximate to 65% did not significantly reduce cardiovascular events in patients with stable coronary heart disease, regardless of the baseline level or the magnitude of change of Lp-PLA(2) activity.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- atherosclerosis
- coronary disease
- inflammation
- lipoprotein
- myocardial infarction
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Wallentin, Lars
-
Held, Claes
-
Armstrong, Paul ...
-
Cannon, Christop ...
-
Davies, Richard ...
-
Granger, Christo ...
-
visa fler...
-
Hagström, Emil
-
Harrington, Robe ...
-
Hochman, Judith ...
-
Koenig, Wolfgang
-
Krug-Gourley, Su ...
-
Mohler, Emile R. ...
-
Siegbahn, Agneta
-
Tarka, Elizabeth
-
Steg, Philippe G ...
-
Stewart, Ralph A ...
-
Weiss, Robert
-
östlund, Ollie
-
White, Harvey D.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Journal of the A ...
- Av lärosätet
-
Uppsala universitet